Moreover, cabozantinib can increase EGFR in RCC cells and reduce PD-L1 membrane surface expression, enhancing the killing ability of CAR-NK-92 cells against renal cell carcinoma (Zhang et al., 2017). This evidence concerns the gene CD274 and renal cell carcinoma.